Patients with ulcerative colitis may be accompanied by extraintestinal manifestations such as skin, mucous membranes, joints, eyes, liver and gallbladder. A clinical pharmacist in the department of gastroenterology took a patient with severe ulcerative colitis complicated with pyoderma gangrenosum and knee arthritis as an example, combined with the patient's disease history, and assisted the doctor in formulating the drug treatment plan and the drug treatment monitoring plan, evaluated the effect of drug treatment and adverse reactions, and actively gave drugs to prevent common adverse reactions; communicated with doctors about drug selection, dosage form, dose and principle of dose reduction, evaluated the risks and benefits of hormone treatment, and educated patients about drug use. From the perspective of pharmacy, clinical pharmacists participated in clinical treatment and optimized treatment plans. While improving patients' awareness of the disease and treatment compliance, they provided patients with individualized medication support to ensure that treatment plans were safe and effective.

1.Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment[J]. J Crohns Colitis, 2022, 16(1): 2-17. DOI: 10.1093/ecco-jcc/jjab178.

2.丁香玉, 李承新. 消化系统疾病的皮肤表现综述[J]. 解放军医学院学报, 2022, 43(1): 106-109. [Ding XY, Li CX. Skin manifestations of digestive diseases: a literature review[J]. Academic Journal of Chinese Pla Medical School, 2022, 43(1): 106-109.] DOI: 10.3969/j.issn.2095-5227.2022.01.020.

3.Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance，surgery, and ileo-anal pouch disorders[J]. J Crohns Colitis, 2017, 11(6): 649-670. DOI: 10.1093/ecco-jcc/jjx008.

4.聂伟杰, 刘家旗, 张锦, 等. 炎症性肠病肠外表现的临床特点及治疗进展[J]. 胃肠病学和肝病学杂志, 2021, 30(2): 225-228. [Nie WJ, Liu JQ, Zhang J, et al. Clinical characteristics and treatment progress of extraintestinal manifestations of inflammatory bowel disease[J]. Chinese Journal of Gastroenterology and Hepatology, 2021, 30(2): 225-228.] DOI: 10.3969/j.issn.1006-5709.2021.02.023.

5.吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 38(9): 796-813. [Wu KC, Liang J, Ran ZH, et al. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(9): 796-813.] DOI: 10.19538/j.nk2018090106.

6.Antonelli E, Bassotti G, Tramontana M, et al. Dermatological manifestations in inflammatory bowel diseases[J]. J Clin Med, 2021, 10(2): 364. DOI: 10.3390/jcm10020364.

7.曾琳茜, 姚越, 黄欣, 等. 生物制剂在坏疽性脓皮病治疗中的研究进展[J/OL]. 中国皮肤性病学杂志, 1-7. [2022-09-06]. [Zeng LX, Yao Y, Huang X, et al. Research progress of biological agents in the treatment of gangrenous pyoderm[J/OL]. Chinese Journal of Dermatovene, 1-7. [2022-09-06].] DOI: 10.13735/j.cjdv.1001-7089.202110142.

8.吴江怡, 陈昊, 杨柳. 骨关节炎的关节腔内注射药物及生物制剂治疗现状[J]. 骨科临床与研究杂志, 2019, 4(2): 113-119. [Wu JY, Chen H, Yang L. Current status of intra-articular injection of drugs and biological agents for treatment of osteoarthritis[J]. Journal of Clinical Orthopedics and Research, 2019, 4(2): 113-119.] DOI: 10.19548/j.2096-269x.2019.02.013.

9.Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review[J]. Int Wound J, 2019, 16(2): 511-521. DOI: 10.1111/iwj.13067.

10.王克甲, 王耘川, 计鹏, 等. 手术治疗坏疽性脓皮病一例[J]. 中华烧伤杂志, 2016, 32(3): 187-188. [Wang KJ, Wang YC, Ji P, et al. Surgical treatment of a case of pyoderma gangrenosum[J]. Chinese Journal of Burns and Wounds, 2016, 32(3): 187-188.] DOI: 10.3760/cma.j. issn.1009-2587.2016.03.014.

11.Reddy N, Rezvani K, Barrett AJ, et al. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients[J]. Biol Blood Marrow Transplant, 2011, 17(5): 591-597. DOI: 10.1016/j.bbmt.2010.08.007.

12.Olivieri I, Cantini F, Castiglione F, et al. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease[J]. Autoimmun Rev, 2014, 13(8): 822-830. DOI: 10.1016/j.autrev.2014.04.003.

13.Chatzinasiou F, Polymeros D, Panagiotou M, et al. Generalized pyoderma gangrenosum associated with ulcerative colitis: successful treatment with infliximab and azathioprine[J]. Acta Dermatovenerol Croat, 2016, 24(1): 83-85. https://pubmed.ncbi.nlm.nih.gov/27149138/.

14.Panaccione R, Ghosh S, Middleton S,  et al. Improvement in patient quality of life during treatment with infliximab, azathioprine, or combination infliximab+azathioprine for moderate-to-severe ulcerative colitis: 1806[J]. Am J Gastroenterol, 2013, 108. DOI: 10.14309/00000434-201310001-01806.